Eli Lil­ly flesh­es out more PhI­II da­ta for Dupix­ent chal­lenger as AD ri­val­ry heats up

Eli Lil­ly out­lined more da­ta for its IL-13 in­hibitor Mon­day as it pre­pares to chal­lenge the megablock­buster Dupix­ent in atopic der­mati­tis.

Lil­ly’s le­brik­izum­ab cleared up …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER